Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002060 · ClinicalTrials.gov registry record · NA
A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Patients With AIDS Related Complex (ARC)
A NA study, sponsored by Newport Pharmaceuticals International.
- Completed
- Registry status
- NA
- Development phase
NCT00002060 is a NA study that has completed, run by Newport Pharmaceuticals International.
The verdict
NCT00002060, a NA study, has completed, sponsored by Newport Pharmaceuticals International.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
The objective is to determine the effect of Isoprinosine (inosine pranobex) in homosexual male patients with AIDS related complex (ARC) in delaying the onset of AIDS. Secondly, to determine the effect of Isoprinosine in decreasing the severity and/or incidence of lesser opportunistic infections and/or other conditions associated with ARC.
Interventions
- DRUG Inosine pranobex
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002060
The ClinicalTrials.gov registry entry for NCT00002060 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Newport Pharmaceuticals International, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Inosine pranobex is the first listed.
NCT00002060 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002060 about?
NCT00002060 is a clinical study titled "A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Patients With AIDS Related Complex (ARC)". The objective is to determine the effect of Isoprinosine (inosine pranobex) in homosexual male patients with AIDS related complex (ARC) in delaying the onset of AIDS. Secondly, to determine the effect of Isoprinosine in decreasing the severity and/or incidence of lesser opportunistic infections and/...
What is the current status of trial NCT00002060?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002060?
The interventions under investigation include: Inosine pranobex (DRUG).
Who is sponsoring clinical trial NCT00002060?
This trial is sponsored by Newport Pharmaceuticals International, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.